Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
TEL AVIV, Israel, June 6, 2013 /PRNewswire/ –
Inspiro Medical [http://www.inspiromedical.com ], a portfolio company of The
Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its
innovative, breath-synchronized, active dry powder inhaler.
The study, completed in May 2013 at Schneider Medical Center aimed to objectively
assess, in a randomized, crossover, double blind study, the efficacy and safety profiles
of formoterol (bronchodilator) treatment via the Inspiromatic in asthmatic children,
compared to its delivery via a competitive inhaler already on the market.
30 children with asthma, aged 8-18, were randomly allocated to treatment with
formoterol via the Inspiromatic inhaler or a competitive device.
The study met both primary and secondary endpoints. The results demonstrated superior
results for of the Inspiromatic in pulmonary delivery of the active drug. Lung function
test (FEV1) demonstrated a statistically significant improvement following formoterol
delivery via the Inspiromatic. Moreover, the Inspiromatic was highly rated by patients.
Successful delivery of the API was achieved even with patients with poor inhalation
technique and even in low-flow inhalation rate.
“I’m very happy with the study results showing that the Inspiromatic achieved safety
and efficacy,” said Nimrod Kaufmann, CEO of Inspiro Medical. “This successful study will
enable us to move to the next step in the company development and partner with
pharmaceutical companies to develop drug-device combinations and also bring better therapy
to patients with poor inhalation technique.”
Despite the numerous aerosol delivery devices currently on the market, Inspiro Medical
believes that their device can significantly improve effectiveness in deposing the
necessary medication. Inspiromatic takes into account drug particle/droplet size; design
of the delivery device; and the patient’s ability to use and understand the device.
Following this successful trial, Inspiro Medical will continue partnering with global
pharmaceutical companies to jointly develop combination products.
Inspiro Medical will be opening investment round A in Q3/2013 to further develop its
device and support partnering activities.
Nimrod Kaufmann will present Inspiro’s proven technology at BioMed 2013 in Tel Aviv on
Company contact details: Nimrod Kaufmann, CEO Tel: +972-72-260-7051 E-mail: email@example.com Website: http://www.inspiromedical.com Media relations: Efrat Kaduri Ofir Shpigel Media and Public Relations +972-4-9535030
SOURCE Inspiro Medical Ltd.